TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05365659: A Phase 1 Cohort Dose Escalation and Expansion Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas (NH

Sponsor: Iksuda Therapeutics Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 140 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$6,817,272

Rescue Site Savings

+$4,492,488

Unlock Full NCT05365659 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05365659 Rescue Dossier →